RTX-240 Monotherapy and in Combination With Pembrolizumab
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Open label, multicenter, multidose, first-in-human Phase 1/2 study of RTX-240 monotherapy or
in combination of pembrolizumab for the treatment of patients with (1) relapsed/refractory
R/R or locally advanced solid tumors (Phase 1/2) or (2) R/R AML (Phase 1 only).